The PK Push has the ability to dramatically improve the outcomes of patients with a wide range of disorders such as Alzheimers, ALS, Multiple sclerosis, fibromyalgia, epilepsy, Lyme disease, chronic fatigue, autism, bipolar disorder, seizures, cardiovascular disease, and more
On an MRI, this appears as a severely obliterated anterior CSF space with clear dural sac compression, and none of the cauda equina can be visibly separated
In contrast, under antioxidant/low-ROS conditions (such as in certain tumor microenvironments or after treatment with BPC157 in our study), BACH1 becomes stabilized and can switch to promoting angiogenesis by directly activating target genes like VEGF
Both studies were conducted in accordance with Good Clinical Practice, the Declaration of Helsinki and US Food and Drug Administration/European Medicines Agency guidelines for studies in people with renal or hepatic impairment [12,13,14,15]